Baxter Q2 Revenue Beats by $160M, Raises 2026 Outlook on Broad Strength
BAX sits 81% above its 52-week low of $15.73.
Summary
Baxter delivered a strong Q2 with revenue of $2.96B, beating consensus by $160M, and adjusted EPS of $0.56, well above the $0.37 estimate. All segments grew in both the U.S. and internationally. Management raised full-year 2026 guidance: reported sales growth now seen at 3%-4% (up from flat-1%) and organic growth at 2%-3% (up from approximately flat). Adjusted EPS guidance was lifted to $1.95-$2.15 from $1.85-$2.05, though $0.11 of the beat came from a one-time tariff refund. Higher-cost inventory and cost reclassifications were partial offsets. The stock surged 15% following the results.
At the time of this announcement, BAX was trading at $28.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.8B. The 52-week trading range was $15.73 to $29.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.